Research · Equities

Glenmark revenue explained: why a 30 percent drop hides a pharmaceutical shift

Glenmark Pharmaceuticals recorded consolidated revenue of Rs 4,247.32 crore in the second quarter of FY27, down from Rs 6,046.87 crore previously.

Financial charts and pharmaceutical laboratory research representing revenue and profit metrics.

Glenmark revenue explained starts with a surprising gap: reported revenue fell 29.8% to Rs. 4,247.32 crore in Q2 FY27, but like-for-like revenue grew around 20%. The difference comes from deferred licensing income linked to its cancer drug pipeline. Its core North American business also grew 31%. Yet profit after tax fell 56.78% to Rs. 263.83 crore, while EBITDA margin dropped to 20.3%. So, is Glenmark's business actually weakening, or do the reported numbers hide a stronger recovery? The answer lies in its regional sales, exceptional costs and ability to turn growth into profit.

What happened

Glenmark Pharmaceuticals reported consolidated revenue from operations of Rs. 4,247.32 crore for the quarter ended September 30, 2026. This was 29.8% lower than the Rs. 6,046.87 crore reported in Q2 FY26.

However, the company also reported around 20% growth on a like-for-like basis in Q2 FY27. This is the number investors should examine before judging the business. The reported decline is affected by deferred out-licensing income linked to ISB 2001, an experimental cancer drug licensed to AbbVie.

North America shows this difference most clearly. Reported revenue from the region fell 72.9% to Rs. 1,208.9 crore in Q2 FY27. But the core business grew around 31% in Q2 FY27 after excluding the deferred licensing income recognition.

Profit was weaker. Consolidated profit after tax fell 56.78% to Rs. 263.83 crore in Q2 FY27 from Rs. 610.43 crore in Q2 FY26. Adjusted PAT for Q2 FY27, which excludes exceptional items, was Rs. 485.2 crore. EBITDA in Q2 FY27 stood at Rs. 863.8 crore, with a margin of 20.3%.

The quarter also included a USD 15 million settlement during Q2 FY27 between Glenmark's US subsidiary and Humana Inc. The settlement related to allegations of anti-competitive conduct in the generic drug market. This was an additional cost during the period, although the settlement did not amount to an admission of liability.

The results therefore show two different trends. Glenmark's underlying business continued to grow, but reported earnings faced pressure from exceptional items and a difficult comparison with the previous year.

Why does revenue explained matter for pharmaceutical stocks?

Revenue tells investors how much a company earns from its business. But it does not always show how well that business is performing.

Pharmaceutical companies often earn money through product sales, licensing deals, milestone payments and partnerships. These income sources do not always follow the same pattern. A large payment recognised in one year can also make the next year's growth look weak.

Glenmark is a good example. Its reported revenue fell almost 30% in Q2 FY27, yet its like-for-like growth was around 20% in Q2 FY27. The difference matters because it changes how investors read the company's performance.

Regional sales offer another useful clue. India formulations grew around 14% on a like-for-like basis in Q2 FY27. Europe's business grew 6.2% in Q2 FY27. Emerging Markets expanded 33.2% in Q2 FY27. North America's core business grew around 31% in Q2 FY27 after adjusting for the licensing income recognition.

But revenue growth alone is not enough. Glenmark's EBITDA margin was 20.3% in Q2 FY27, and its reported PAT was much lower than its adjusted PAT. Investors must ask whether sales growth can lead to better margins and cash generation.

This is the real purpose of revenue explained: separating changes in reported income from changes in the underlying business. In broader stock market explained terms, it helps investors avoid treating every fall in quarterly sales as a sign of business failure.

For a broader look at how company performance and market risks affect investment decisions, read Vestmind's stock analysis methodology.

What are the exact figures behind Glenmark's Q2 FY27 results?

Glenmark's quarterly results show a clear gap between reported performance and underlying growth.

The main financial figures are:

• Consolidated revenue: Rs. 4,247.32 crore in Q2 FY27, down 29.8% year-on-year. • Like-for-like consolidated revenue growth: approximately 20% in Q2 FY27. • Reported PAT: Rs. 263.83 crore in Q2 FY27, down 56.78% year-on-year. • Adjusted PAT for Q2 FY27: Rs. 485.2 crore. • EBITDA for Q2 FY27: Rs. 863.8 crore. • EBITDA margin in Q2 FY27: 20.3%. • Consolidated R&D spending in Q2 FY27: Rs. 344.9 crore.

Regional sales also reveal important differences.

India formulations generated Rs. 1,327.4 crore in revenue in Q2 FY27. The like-for-like growth rate was around 14% in Q2 FY27. North America reported Rs. 1,208.9 crore in Q2 FY27, down 72.9%, but its core business grew around 31% in Q2 FY27. Europe generated Rs. 792 crore in Q2 FY27, up 6.2%. Emerging Markets recorded Rs. 876.9 crore in Q2 FY27, up 33.2%.

One important detail is the gap between adjusted and reported PAT. The company reported adjusted PAT of Rs. 485.2 crore for Q2 FY27 after excluding exceptional items. Reported PAT for Q2 FY27 was Rs. 263.83 crore. Investors should not treat these figures as interchangeable. Reported earnings include the impact of exceptional charges.

Glenmark also maintained its FY27 guidance. It expects consolidated revenue of Rs. 17,000-18,000 crore, with margins of 21-22%. These targets give investors a clear benchmark for tracking the next two quarters.

What does this mean for your portfolio?

Glenmark's results offer an important lesson in why having revenue explained matters when reading quarterly earnings. A sharp fall in reported revenue does not always mean the core business is shrinking.

An investor looking only at the 29.8% revenue decline in Q2 FY27 might conclude that Glenmark is losing ground. But its 20% like-for-like growth in Q2 FY27 tells a different story. The North American recovery and growth across Emerging Markets also support this view.

However, there are risks. EBITDA margin fell sharply from the previous year's level. Reported PAT also remained well below adjusted PAT. The company must now show that its sales growth can support stronger profits.

Investors holding pharma stocks should also check their sector exposure. A portfolio with several drug companies may still carry high risk if those companies depend on the same export markets or product categories.

This is where the idea of havens explained in asset allocation becomes relevant, but with an important distinction. Defensive sectors are not risk-free. Pharmaceutical stocks can face regulatory action, pricing pressure, legal costs and delays in product approvals. They should not be treated as automatic safe havens during market volatility.

Review the weight of pharmaceutical stocks in your portfolio. Also check the underlying companies held by your mutual funds. This helps you see whether you have more exposure to one company or sector than you intended.

Vestmind's view

With Glenmark's revenue explained, the Q2 FY27 results are better than the headline revenue decline suggests, but they are not an all-clear signal.

The positive case rests on three factors. Like-for-like revenue grew around 20% in Q2 FY27. North America's core business expanded 31% in Q2 FY27. Emerging Markets delivered 33.2% growth in Q2 FY27. These numbers suggest that the company's base business has momentum.

The concern is profitability. EBITDA margin stood at 20.3% in Q2 FY27, and reported PAT fell 56.78% in Q2 FY27. The gap between adjusted and reported earnings also shows why investors must look closely at exceptional costs.

We would become more positive if Glenmark sustains its regional growth, improves margins and meets its FY27 guidance. We would turn cautious if sales momentum slows or earnings remain weak despite higher revenue.

Our conclusion: the market should not judge Glenmark only by its 29.8% reported revenue decline. But the company must now prove that strong underlying growth can translate into lasting profit growth.

What to watch next

Three developments will matter most in Glenmark's next results.

First, watch North America. Its core business grew around 31% in Q2 FY27 after excluding deferred licensing income. Investors should check whether new product launches can sustain this recovery.

Second, track operating margins and reported profit. EBITDA margin stood at 20.3% in Q2 FY27. Adjusted PAT for Q2 FY27 was Rs. 485.2 crore, against reported PAT of Rs. 263.83 crore. Stronger margins and a smaller gap between adjusted and reported earnings would improve confidence in the quality of profits.

Third, follow the oncology pipeline. Glenmark expects the first commercial launch from its partnered innovative oncology pipeline by the end of FY27. Its innovation subsidiary has also selected Phase 1 data for ISB 2001 for an oral presentation at the 2026 American Society of Hematology meeting. The company plans to submit an investigational new drug application for ISB 2301 by the end of calendar year 2026.

Also watch RYALTRIS, its international launches and the company's progress towards FY27 revenue guidance of Rs. 17,000-18,000 crore.

The next two quarters will help answer the bigger question: can Glenmark turn strong underlying sales growth into stronger and more consistent earnings?

Frequently asked

What was Glenmark Pharmaceuticals' revenue in Q2 FY27?

Glenmark reported consolidated revenue from operations of Rs. 4,247.32 crore in Q2 FY27, down 29.8% from Rs. 6,046.87 crore in Q2 FY26. However, its like-for-like consolidated revenue grew around 20% year-on-year.

Why did Glenmark's revenue fall despite underlying business growth?

Glenmark's revenue explained shows that the reported decline was affected by deferred out-licensing income recognition linked to ISB 2001, its partnered oncology asset. Excluding this effect and using the company's like-for-like comparison, consolidated revenue grew around 20%. North America's core business also grew around 31%.

What was Glenmark's profit after tax in Q2 FY27?

Glenmark reported consolidated PAT of Rs. 263.83 crore, down 56.78% year-on-year. Adjusted PAT was Rs. 485.2 crore after excluding exceptional items. The difference highlights the impact of exceptional charges on reported earnings.

How did Glenmark's regional businesses perform?

India formulations grew around 14% on a like-for-like basis. North America's core business grew around 31%, Europe expanded 6.2%, and Emerging Markets grew 33.2%. North America's reported revenue was lower because of the licensing income comparison.

What is Glenmark's revenue guidance for FY27?

Glenmark maintained its FY27 consolidated revenue guidance of Rs. 17,000-18,000 crore. It also retained its margin guidance of 21-22%. Investors can use these targets to assess the company's performance in the second half of the financial year.

When does Glenmark expect its oncology pipeline launch?

Glenmark expects the first commercial launch from its partnered innovative oncology pipeline by the end of FY27. It is also advancing ISB 2001 and plans to submit an investigational new drug application for ISB 2301 by the end of calendar year 2026.

Is Glenmark's Q2 FY27 performance a positive sign for investors?

The results are mixed. Like-for-like revenue growth of around 20% and strong regional performance are positive signs. However, the 56.78% fall in reported PAT and lower EBITDA margin remain concerns. Investors should watch future earnings, margins and progress against FY27 guidance before drawing conclusions.

Comments

Log in to join the discussion.

    Sources & methodology

    This article uses Glenmark Pharmaceuticals' Q2 FY27 investor presentation, company disclosures and management commentary as primary sources. Independent financial reporting is used for cross-checking. Reported revenue is distinguished from like-for-like growth. Adjusted PAT is distinguished from reported PAT, and regional growth rates are presented on the basis specified by the company. No unrelated market benchmarks or unverified macroeconomic figures have been included. This article is for financial education and does not constitute investment advice.

    1. Glenmark Pharmaceuticals Q2 FY27 Investor Presentation Glenmark Pharmaceuticals Primary source for consolidated and regional revenue, like-for-like growth, EBITDA, adjusted PAT, R&D spending and FY27 guidance.
    2. Glenmark Pharmaceuticals Q2 FY27 Press Release and Management Discussion Glenmark Pharmaceuticals Company-issued management discussion covering quarterly performance, licensing income, regional growth, oncology pipeline and management outlook.
    3. Glenmark Pharma Q2 Revenue Falls 30% to Rs. 4,247 Crore, Profit Down 57% Business Standard Independent reporting of reported revenue, PAT and the impact of exceptional items.
    4. Glenmark Net Profit Plunges 56% to Rs. 264 Crore in Q2 FY27 ET Pharma Reported earnings, regional sales, Humana settlement and management's FY27 guidance.
    5. Glenmark Pharmaceuticals Q2 FY27 Earnings Call Transcript AlphaStreet Management discussion on like-for-like revenue, adjusted earnings, business recovery and operating outlook.
    6. Stock Analysis Methodology Vestmind Research Internal link explaining how company financials, business quality, valuation and investment risks should be assessed.
    7. Vestmind Research Vestmind Internal research library for further reading on Indian equities, global markets and portfolio risks.